Abstract
A series of novel aminomethyl-piperidones were designed and evaluated as potential DPP-IV inhibitors. Optimized analogue 12v ((4S,5S)-5-(aminomethyl)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-4-(2,5-difluorophenyl)piperidin-2-one) showed excellent in vitro potency and selectivity for DPP-IV over other serine proteases. The lead compound 12v showed potent and long acting antihyperglycemic effects (in vivo), along with improved pharmacokinetic profile.
Keywords:
Aminomethyl-piperidones; Antidiabetic; DPP-IV inhibitors; Long-acting; Selective.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Catalytic Domain
-
Dipeptidyl-Peptidase IV Inhibitors / chemical synthesis
-
Dipeptidyl-Peptidase IV Inhibitors / chemistry
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacology
-
Drug Design*
-
Enzyme Activation / drug effects*
-
Hypoglycemic Agents / chemical synthesis
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Inhibitory Concentration 50
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Models, Molecular
-
Molecular Structure
-
Piperidones / chemical synthesis*
-
Piperidones / chemistry
-
Piperidones / pharmacology*
-
Pyrazines / chemistry
-
Pyrazines / pharmacology
-
Sitagliptin Phosphate
-
Triazoles / chemistry
-
Triazoles / pharmacology
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Piperidones
-
Pyrazines
-
Triazoles
-
Sitagliptin Phosphate